Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817866 · ClinicalTrials.gov registry record
Chromogranin A as Blood Marker in Cancer Patients
A clinical trial of Colorectal Neoplasms and Pancreatic Neoplasms, sponsored by Brahms.
- Completed
- Registry status
- 175
- Enrollment target
- 4
- Study locations
NCT03817866 is a study of Colorectal Neoplasms and Pancreatic Neoplasms that has completed, run by Brahms. The registered enrollment target is 175 participants, below the 573-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03817866, a study of Colorectal Neoplasms and Pancreatic Neoplasms, has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 175 participants
- Enrollment target
- 4
- Study locations
Study Summary
Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs. Due to the lack of symptoms in the early stage of disease and the frequency of nonspecific GI symptoms, GEP-NETs are difficult to diagnose. Identification of effective biomarkers (such as Chromogranin A) to improve GEP-NET diagnosis, as well as to assess treatment efficacy, relapse and prognosis, is important for improving outcomes for patients with GEP-NETs. The purpose of this study is to validate the performance of Brahms (BRAHMS) Chromogranin A II Kryptor (KRYPTOR) assay to monitor the course of disease in patients with well-defined GEP-NETs.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST BRAHMS CgA II KRYPTOR
Study Locations (4)
California
- Stanford University Medical Center - Palo Alto
Minnesota
- Mayo Clinic - Rochester
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Other
- Charité - Universitätsmedizin Berlin - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2021-12-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817866
The ClinicalTrials.gov registry entry for NCT03817866 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 573-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (69% lower). The listed sponsor is Brahms, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which BRAHMS CgA II KRYPTOR is the first listed.
NCT03817866 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT03817866 about?
NCT03817866 is a clinical study titled "Chromogranin A as Blood Marker in Cancer Patients". Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs. Due to the lack of symptoms in the early stage of disease and the frequ...
What is the current status of trial NCT03817866?
This trial is currently completed. The enrollment target is 175 participants. The study started on 2019-01-29. Estimated completion is 2021-12-14.
What conditions does trial NCT03817866 study?
This clinical trial studies the following conditions: Colorectal Neoplasms, Pancreatic Neoplasms, Gastric Neoplasms, Small Intestinal Neoplasms.
What interventions are being tested in trial NCT03817866?
The interventions under investigation include: BRAHMS CgA II KRYPTOR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03817866?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817866 being conducted?
This trial has 4 study locations across California, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
RECRUITING · Phase 3
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.